<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01222312</url>
  </required_header>
  <id_info>
    <org_study_id>S417</org_study_id>
    <nct_id>NCT01222312</nct_id>
  </id_info>
  <brief_title>Study for Therapy of Locally Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC) With Cisplatin / Docetaxel or Oxaliplatin / Docetaxel</brief_title>
  <acronym>Taxelox</acronym>
  <official_title>Multicenter Randomized Phase II Study for the Therapy of Locally Advanced or Metastatic NSCLC (Stage IIIB/IV) With Cisplatin/Docetaxel or Oxaliplatin/Docetaxel</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Krankenhaus Nordwest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Krankenhaus Nordwest</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study compares two combinations of chemotherapy in patients with advanced or metastatic
      NSCLC: 50% of the patients are treated with cisplatin and docetaxel, the other 50% with
      oxaliplatin and docetaxel. cisplatin is today the standard therapy, but the toxicity profile
      is often not tolerable. Especially in elderly patients or patients with comorbidities,
      oxaliplatin based chemotherapy may have lower toxicities but comparable or even better
      response rates.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cispaltin based chemotherapies are standard for palliative first-line therapy in patients
      with advanced or metastatic NSCLC. Due to contraindications to cisplatin, this substance can
      not be used in a high number of patients. Especially in elderly patients, patients with
      comorbidities and patients with reduced general condition, cisplatin is a therapy which often
      induces intolerable toxicities. Thus, therapy often has to be interrupted or finished
      prematurely. Due to its favorable toxicity profile, oxaliplatin can be used also for the
      treatment of elderly patients and patients with comorbidities. Based on toxicity data from a
      phase II study of our group in patients with gastric cancer, the dosage for
      oxaliplatin/docetaxel was adopted for this actual study. In previous phase II trials,
      response rates of oxaliplatin based combination chemotherapies were comparable to those with
      cisplatin in patients with metastatic NSCLC.

      In this study we will analyse, if a oxaliplatin based combination chemotherapy has a more
      tolerable toxicity profile and comparable or even better response rate in comparison to a
      cisplatin based chemotherapy. 44 patients in each arm will either be treated with a maximum
      of 6 cycles cisplatin/docetaxel or a maximum of 8 cycles oxaliplatin/docetaxel.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>response rate</measure>
    <time_frame>staging every 2 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>every two weeks</time_frame>
    <description>comparison of adverse events (all grades, grade 3/4) in the Cisplatin vs Oxaliplatin arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>every 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression free survival PFS</measure>
    <time_frame>every 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival OS</measure>
    <time_frame>6 months follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to treatment failure TTF</measure>
    <time_frame>every two weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">88</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A cisplatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cisplatin 75 mg/m2, d1 Docetaxel 75 mg/m2, d1 every 3 weeks (d22) max. 6 cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B oxaliplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oxaliplatin 85 mg/m², d1 Docetaxel 50mg/m2, d1 every 2 weeks (d15) max. 8 cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>75 mg/m2, d1 every 3 weeks</description>
    <arm_group_label>Arm A cisplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>85 mg/m², d1 every 2 weeks</description>
    <arm_group_label>Arm B oxaliplatin</arm_group_label>
    <other_name>Eloxatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>75 mg/m2, d1 every 3 weeks</description>
    <arm_group_label>Arm A cisplatin</arm_group_label>
    <other_name>Taxotere</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>50mg/m2, d1 every 2 weeks</description>
    <arm_group_label>Arm B oxaliplatin</arm_group_label>
    <other_name>Taxotere</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  histologically or cytologically confirmed NSCLC stage IIIB or IV.

          -  no previous chemotherapy in metastatic state

          -  male and female patients aged &gt; 18 years

          -  ECOG ≤ 2

          -  Leukocytes &gt; 3.000/µl

          -  Thrombocytes &gt; 100.000/µl

          -  Serum creatinine ≤ 1.25x normal value, or Creatinine Clearance &gt; 45 ml/min

          -  previous radiation &lt; 25% bone marrow region allowed. Previous radiation of whole
             pelvis not allowed

          -  parallel radiation allowed, if target lesion outside of radiation field

          -  written informed consent

          -  life expectancy &gt; 3 months

        Exclusion Criteria:

          -  hypersensibility against Cisplatin, Oxaliplatin or Docetaxel

          -  Neoadjuvant or adjuvant chemotherapy within the last 6 months

          -  radiation within the last 28 days

          -  severe systemic comorbidities

          -  Cardiomyopathy or cardiac insufficiency stage II-IV according to NYHA

          -  malignant secondary disease, dated back &lt; 5 years (exception: In-situ-carcinoma of the
             cervix uteri, adequately treated skin basal cell carcinoma)

          -  brain metastases

          -  severe non-surgical comorbidities or acute infection

          -  peripheral polyneuropathy &gt; NCI grade II

          -  severe liver dysfunction AST/ALT&gt;3,5xULN, AP&gt;6xULN, Bilirubin&gt;1,5xULN)

          -  participation in parallel trial

          -  pregnancy and lactation

          -  reduced hearing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elke Jäger, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Krankenhaus Nordwest</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Krankenhaus Nordwest</name>
      <address>
        <city>Frankfurt/Main</city>
        <zip>60488</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 12, 2010</study_first_submitted>
  <study_first_submitted_qc>October 14, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 18, 2010</study_first_posted>
  <last_update_submitted>November 28, 2011</last_update_submitted>
  <last_update_submitted_qc>November 28, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 29, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>advanced NSCLC</keyword>
  <keyword>oxaliplatin</keyword>
  <keyword>cisplatin</keyword>
  <keyword>docetaxel</keyword>
  <keyword>locally advanced or metastatic non small cell lung cancer (stage IIIB-IV)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

